Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.
Exploring the companies and themes that make up this emerging and exciting new sector
U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening
Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
Mydecine Announces Size of Previously Announced Overnight Marketed Public Offering of Units
Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
Albert Labs Granted Health Canada Licence
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
Awakn Life Sciences announces the appointment of noted expert in addictions psychiatry, Dr. Arun Dhandayudham as its new CMO.
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea
Incannex Healthcare announces a positive Pre-Investigational New Drug Application meeting with the FDA concerning IHL-42X, a compound for treating sleep apnoea.
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
Cybin Inc announces that it will take part in the NYSE's "morning bell" ceremony for the May 18th trading session.
MindMed Announces At-The-Market Offering
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.
Major Step Forward For PTSD Treatment And The Psychedelics Industry
A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.
Red Light Holland Successfully Imports 200 Psilocybin iMicrodose Packs, Sold in The Netherlands, Into Canada Under a Third Health Canada Approved Psilocybin Import Permit To cGMP Laboratory
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.